Advanced search
Add to list

International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))

(2016) ONCOLOGY RESEARCH AND TREATMENT. 39(suppl. 3). p.6-6
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Burger, J., et al. “International, Randomized Phase 3 Study Results : Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naive CLL (RESONATE-2 (TM)).” ONCOLOGY RESEARCH AND TREATMENT, vol. 39, no. suppl. 3, 2016, pp. 6–6.
APA
Burger, J., Tedeschi, A., Barr, P., Robak, T., Owen, C., Ghia, P., … Kipps, T. (2016). International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)). ONCOLOGY RESEARCH AND TREATMENT, 39(suppl. 3), 6–6.
Chicago author-date
Burger, J, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, et al. 2016. “International, Randomized Phase 3 Study Results : Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naive CLL (RESONATE-2 (TM)).” In ONCOLOGY RESEARCH AND TREATMENT, 39:6–6.
Chicago author-date (all authors)
Burger, J, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, P Hillmen, NL Bartlett, J Li, D Simpson, S Grosicki, S Devereux, H Mccarthy, S Coutre, H Quach, G Gaidano, Z Maslyak, DA Stevens, A Janssens, Fritz Offner, J Mayer, M O’Dwyer, A Hellmann, A Schuh, T Siddiqi, A Polliack, CS Tam, D Suri, M Cheng, F Clow, L Styles, DF James, and TJ Kipps. 2016. “International, Randomized Phase 3 Study Results : Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naive CLL (RESONATE-2 (TM)).” In ONCOLOGY RESEARCH AND TREATMENT, 39:6–6.
Vancouver
1.
Burger J, Tedeschi A, Barr P, Robak T, Owen C, Ghia P, et al. International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)). In: ONCOLOGY RESEARCH AND TREATMENT. 2016. p. 6–6.
IEEE
[1]
J. Burger et al., “International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)),” in ONCOLOGY RESEARCH AND TREATMENT, Leipzig, Germany, 2016, vol. 39, no. suppl. 3, pp. 6–6.
@inproceedings{8509429,
  articleno    = {{abstract V34}},
  author       = {{Burger, J and Tedeschi, A and Barr, PM and Robak, T and Owen, C and Ghia, P and Bairey, O and Hillmen, P and Bartlett, NL and Li, J and Simpson, D and Grosicki, S and Devereux, S and Mccarthy, H and Coutre, S and Quach, H and Gaidano, G and Maslyak, Z and Stevens, DA and Janssens, A and Offner, Fritz and Mayer, J and O'Dwyer, M and Hellmann, A and Schuh, A and Siddiqi, T and Polliack, A and Tam, CS and Suri, D and Cheng, M and Clow, F and Styles, L and James, DF and Kipps, TJ}},
  booktitle    = {{ONCOLOGY RESEARCH AND TREATMENT}},
  issn         = {{2296-5270}},
  language     = {{eng}},
  location     = {{Leipzig, Germany}},
  number       = {{suppl. 3}},
  pages        = {{abstract V34:6--abstract V34:6}},
  title        = {{International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))}},
  volume       = {{39}},
  year         = {{2016}},
}

Web of Science
Times cited: